Andrew Partridge
Corporate Officer/Principal bei TURG POIN
Aktive Positionen von Andrew Partridge
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| TURG POIN | Corporate Officer/Principal | 13.07.2020 | - |
Karriereverlauf von Andrew Partridge
Ehemalige bekannte Positionen von Andrew Partridge
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CENTREXION THERAPEUTICS CORPORATION | Corporate Officer/Principal | 24.09.2018 | 02.07.2020 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.01.2013 | 01.11.2018 |
| AMGEN INC. | Vertrieb & Marketing | 01.01.2003 | 01.01.2013 |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 3 |
| Sales & Marketing | 1 |
Sektoral
| Health Technology | 5 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
- Börse
- Insiders
- Andrew Partridge
- Erfahrung